Money Concepts Capital Corp decreased its stake in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 67.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 530 shares of the company's stock after selling 1,087 shares during the period. Money Concepts Capital Corp's holdings in Zoetis were worth $92,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Rehmann Capital Advisory Group boosted its holdings in shares of Zoetis by 1.7% during the 4th quarter. Rehmann Capital Advisory Group now owns 3,559 shares of the company's stock worth $869,000 after buying an additional 58 shares during the period. Norway Savings Bank boosted its stake in shares of Zoetis by 1.8% in the second quarter. Norway Savings Bank now owns 3,304 shares of the company's stock valued at $568,000 after buying an additional 60 shares during the period. Salvus Wealth Management LLC boosted its stake in shares of Zoetis by 3.9% in the first quarter. Salvus Wealth Management LLC now owns 1,631 shares of the company's stock valued at $308,000 after buying an additional 61 shares during the period. Redpoint Investment Management Pty Ltd grew its position in Zoetis by 0.5% during the second quarter. Redpoint Investment Management Pty Ltd now owns 12,803 shares of the company's stock worth $2,201,000 after buying an additional 66 shares in the last quarter. Finally, Telemus Capital LLC grew its position in Zoetis by 4.0% during the first quarter. Telemus Capital LLC now owns 1,753 shares of the company's stock worth $331,000 after buying an additional 67 shares in the last quarter. Institutional investors own 91.05% of the company's stock.

Zoetis Stock Down 1.8 %

Shares of ZTS opened at $148.29 on Friday. Zoetis Inc. has a 52 week low of $147.77 and a 52 week high of $249.27. The stock has a market capitalization of $69.42 billion, a price-to-earnings ratio of 33.63, a PEG ratio of 2.64 and a beta of 0.77. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18. The stock has a fifty day moving average of $164.42 and a 200-day moving average of $171.87.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ZTS shares. Stifel Nicolaus reduced their price target on Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a research report on Friday, June 24th. The Goldman Sachs Group reduced their price target on Zoetis from $208.00 to $202.00 and set a "buy" rating on the stock in a research report on Thursday, July 21st. Piper Sandler began coverage on Zoetis in a research report on Monday, July 11th. They set an "overweight" rating and a $205.00 price target on the stock. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a report on Friday, August 5th. Finally, StockNews.com downgraded Zoetis from a "strong-buy" rating to a "buy" rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $224.00.

Insider Buying and Selling

In related news, CEO Kristin C. Peck sold 9,689 shares of the firm's stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Kristin C. Peck sold 9,689 shares of Zoetis stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kristin C. Peck sold 311 shares of Zoetis stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at $7,153,740. The disclosure for this sale can be found here. Insiders sold a total of 12,167 shares of company stock valued at $2,190,623 in the last three months. Insiders own 0.12% of the company's stock.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

• Get a free copy of the StockNews.com research report on Zoetis (ZTS)
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• Thor Industries Hammers Out A Bottom
• How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.